Anaptysbio Inc (ANAB)

$31.37 -0.40 (-1.26%)
Market Cap 889.46M
Revenue (ttm) 91.28M
Net Income (ttm) -145.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -159.10%
Debt to Equity Ratio 0.00
Volume 212,100
Avg Vol 568,458
Day's Range N/A - N/A
Shares Out 28.00M
Stochastic %K 75%
Beta -0.18
Analysts Strong Sell
Price Target $53.18

Company Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared co...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 362 6295
Address:
10770 Wateridge Circle, Suite 210, San Diego, United States
Trendrebel
Trendrebel Oct. 7 at 6:57 AM
$ANAB All eyes on gap fill
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 1:09 AM
$ANAB: Unusual Options Activity Alerted CALL flow observed 15x contracts at Strike price of $12.5 Exp on 02/20/2026 with Premium of $32K and showing NEUTRAL Sentiment
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:22 PM
$SNDK $CLPT $ERAS $ANAB Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
RunnerSignals
RunnerSignals Oct. 2 at 11:35 AM
Biotech Gets Bullish $LRMR $CRSP $ANAB receiving major analyst upgrades with serious upside targets https://stocksrunner.com/news/2025-10-02-stock-upgrades-today-with-top-analyst-picks-you-need-to-know
0 · Reply
BringBackDollarDogs
BringBackDollarDogs Oct. 2 at 3:27 AM
$ANAB So I'm giving fresh release here to any degenerates. Lemme know what you think https://netcorelinuxtemplate-a7f7cyhbfabwcsc3.eastus2-01.azurewebsites.net/Home/Index
0 · Reply
56kw
56kw Oct. 1 at 4:53 PM
$ANAB Bought my tickets, let's see what happens
0 · Reply
inelegantinvest
inelegantinvest Oct. 1 at 4:00 PM
$ANAB +30% after announcing a spinoff: 👉 Royalty Co will own Jemperli & imsidolimab rights 👉 Biopharma Co keeps rosnilimab, ANB033, ANB101 Full breakdown: https://www.stockspinoffs.com/2025/10/01/anaptysbio-spinoff-news-sends-stock-up-more-than-30/
0 · Reply
Winning_calls
Winning_calls Oct. 1 at 1:53 PM
$ANAB 🤔🫡
0 · Reply
StockBraker
StockBraker Oct. 1 at 2:16 AM
$ANAB
0 · Reply
FurrrMom
FurrrMom Oct. 1 at 1:29 AM
$ANAB & $AIIO more in the tank. $PAVS highest conviction setup and largest hold. $1 area should see $3 by week's end. Watching $DJT for long term.
0 · Reply
Latest News on ANAB
AnaptysBio Charts Path To Split Into Two Public Companies By 2026

Sep 30, 2025, 1:59 PM EDT - 10 days ago

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

AnaptysBio, Inc. - Special Call

Sep 29, 2025, 9:27 PM EDT - 11 days ago

AnaptysBio, Inc. - Special Call

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Sep 29, 2025, 4:05 PM EDT - 11 days ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Sep 29, 2025, 4:05 PM EDT - 11 days ago

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Anaptys Announces Participation in September Investor Conferences

Aug 27, 2025, 4:15 PM EDT - 6 weeks ago

Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:15 PM EDT - 2 months ago

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

Jun 10, 2025, 1:33 PM EDT - 4 months ago

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

Jun 6, 2025, 3:39 PM EDT - 4 months ago

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Jun 4, 2025, 2:23 PM EDT - 4 months ago

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Jun 3, 2025, 4:05 PM EDT - 4 months ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

May 27, 2025, 4:15 PM EDT - 4 months ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:15 PM EDT - 5 months ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Stock Repurchase Plan

Mar 24, 2025, 9:15 AM EDT - 7 months ago

Anaptys Announces Stock Repurchase Plan

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:15 PM EST - 8 months ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Anaptys Announces Participation in March Investor Conferences

Feb 27, 2025, 4:15 PM EST - 8 months ago

Anaptys Announces Participation in March Investor Conferences

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 12, 2025, 7:30 AM EST - 8 months ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Feb 11, 2025, 5:30 PM EST - 8 months ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 4:15 PM EST - 8 months ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Feb 3, 2025, 7:30 AM EST - 8 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 9:15 AM EST - 9 months ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Dec 11, 2024, 2:07 PM EST - 10 months ago

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

AnaptysBio to abandon eczema drug development after mid-stage trial failure

Dec 11, 2024, 10:20 AM EST - 10 months ago

AnaptysBio to abandon eczema drug development after mid-stage trial failure

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:42 AM EST - 10 months ago

AnaptysBio abandons eczema drug development after mid-stage trial failure

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Dec 11, 2024, 8:30 AM EST - 10 months ago

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Anaptys Announces Participation in November and December Investor Conferences

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in November and December Investor Conferences

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 15, 2024, 2:14 PM EDT - 1 year ago

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Aug 14, 2024, 5:00 AM EDT - 1 year ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

Jul 22, 2024, 2:53 PM EDT - 1 year ago

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

May 9, 2024, 4:10 PM EDT - 1 year ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

May 9, 2024, 4:05 PM EDT - 1 year ago

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Actym Therapeutics Appoints Thomas Smart as CEO

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

PGEN XOMA

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 11, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

Feb 29, 2024, 9:15 AM EST - 1 year ago

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference

Jan 31, 2024, 9:15 AM EST - 1 year ago

Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Nov 27, 2023, 4:15 PM EST - 2 years ago

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

Anaptys Named a BioSpace 2024 Best Places to Work Winner

Nov 7, 2023, 4:15 PM EST - 2 years ago

Anaptys Named a BioSpace 2024 Best Places to Work Winner

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 2, 2023, 4:15 PM EDT - 2 years ago

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

Anaptys Announces Participation in November Investor Conferences

Nov 1, 2023, 9:15 AM EDT - 2 years ago

Anaptys Announces Participation in November Investor Conferences

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

Oct 11, 2023, 9:15 AM EDT - 2 years ago

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

AnaptysBio's skin disease drug meets main goal in late-stage study

Oct 9, 2023, 8:32 AM EDT - 2 years ago

AnaptysBio's skin disease drug meets main goal in late-stage study

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

Oct 9, 2023, 8:15 AM EDT - 2 years ago

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

Oct 9, 2023, 8:00 AM EDT - 2 years ago

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

Sep 18, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

Sep 12, 2023, 9:15 AM EDT - 2 years ago

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

Aug 7, 2023, 4:15 PM EDT - 2 years ago

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

Jul 31, 2023, 1:34 PM EDT - 2 years ago

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

AnaptysBio: Despite Early Successes, Current Situation Does Not Impress

Jul 7, 2023, 10:33 AM EDT - 2 years ago

AnaptysBio: Despite Early Successes, Current Situation Does Not Impress

Trendrebel
Trendrebel Oct. 7 at 6:57 AM
$ANAB All eyes on gap fill
0 · Reply
SweepCastApp
SweepCastApp Oct. 4 at 1:09 AM
$ANAB: Unusual Options Activity Alerted CALL flow observed 15x contracts at Strike price of $12.5 Exp on 02/20/2026 with Premium of $32K and showing NEUTRAL Sentiment
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:22 PM
$SNDK $CLPT $ERAS $ANAB Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve.
0 · Reply
RunnerSignals
RunnerSignals Oct. 2 at 11:35 AM
Biotech Gets Bullish $LRMR $CRSP $ANAB receiving major analyst upgrades with serious upside targets https://stocksrunner.com/news/2025-10-02-stock-upgrades-today-with-top-analyst-picks-you-need-to-know
0 · Reply
BringBackDollarDogs
BringBackDollarDogs Oct. 2 at 3:27 AM
$ANAB So I'm giving fresh release here to any degenerates. Lemme know what you think https://netcorelinuxtemplate-a7f7cyhbfabwcsc3.eastus2-01.azurewebsites.net/Home/Index
0 · Reply
56kw
56kw Oct. 1 at 4:53 PM
$ANAB Bought my tickets, let's see what happens
0 · Reply
inelegantinvest
inelegantinvest Oct. 1 at 4:00 PM
$ANAB +30% after announcing a spinoff: 👉 Royalty Co will own Jemperli & imsidolimab rights 👉 Biopharma Co keeps rosnilimab, ANB033, ANB101 Full breakdown: https://www.stockspinoffs.com/2025/10/01/anaptysbio-spinoff-news-sends-stock-up-more-than-30/
0 · Reply
Winning_calls
Winning_calls Oct. 1 at 1:53 PM
$ANAB 🤔🫡
0 · Reply
StockBraker
StockBraker Oct. 1 at 2:16 AM
$ANAB
0 · Reply
FurrrMom
FurrrMom Oct. 1 at 1:29 AM
$ANAB & $AIIO more in the tank. $PAVS highest conviction setup and largest hold. $1 area should see $3 by week's end. Watching $DJT for long term.
0 · Reply
NocturneBloom
NocturneBloom Sep. 30 at 10:49 PM
$ANAB Looking great
0 · Reply
fallondpicks
fallondpicks Sep. 30 at 10:25 PM
25 #stockbreakouts $ANAB (gap), $PATH (gap), $PPH (base), $UNFI (gap). Eight sub-$1, two $1-2
0 · Reply
topstockalerts
topstockalerts Sep. 30 at 8:54 PM
Top Gainers PT2 $SPRC $BKKT $ANAB $WOLF $CASI
0 · Reply
topstockalerts
topstockalerts Sep. 30 at 8:10 PM
Top Gainers PT2 $SPRC $SKYQ $ANAB $BKKT $CASI
0 · Reply
GoldenBayAssets
GoldenBayAssets Sep. 30 at 6:30 PM
$ANAB SHOT strong hands soaked 0.266s, ladder built 0.269 then 0.271, continuation into 0.279 likely, PT $.30
0 · Reply
topstockalerts
topstockalerts Sep. 30 at 5:31 PM
$ANAB primed for continuation.. ✅📈 Stay tuned bulls!!
0 · Reply
DARKP00L
DARKP00L Sep. 30 at 5:31 PM
$ANAB the market is buzzing about this stock. Expect possible price changes!
0 · Reply
DARKP00L
DARKP00L Sep. 30 at 5:03 PM
$ANAB 13:01 on Sep. 30 2025 AnaptysBio's Split Announcement Seems 'Awkward' Amid Clinical Activities, Truist Securities Says #tradeideas
0 · Reply
StocktwitsNews
StocktwitsNews Sep. 30 at 4:44 PM
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level $ANAB $VFMO $UWM https://stocktwits.com/news/equity/markets/anaptysbio-stock-gets-price-target-hike-after-announcing-plan-to-separate-royalty-biopharma-business/chDDWF9R39Q
0 · Reply
topstockalerts
topstockalerts Sep. 30 at 4:39 PM
Top Gainers PT2 $DPRO $ANAB $VOR $AIIO $FATE
0 · Reply
CommercialREbroker
CommercialREbroker Sep. 30 at 3:11 PM
$ANAB going to crater
1 · Reply
topstockalerts
topstockalerts Sep. 30 at 3:10 PM
$ANAB showing high relative strength..
0 · Reply